Mental disorders and diabetes mellitus;Psychische Erkrankungen und Diabetes mellitus

Wiener Klinische Wochenschrift

Volumn 128, Issue , 2016, Pages 170-178

  Abrahamian, Heidemarie ^a   Kautzky Willer, Alexandra ^b   Rießland Seifert, Angelika ^a   Fasching, Peter ^c   Ebenbichler, Christoph ^d   Hofmann, Peter ^e   Toplak, Hermann ^d  

^a Wiener Krankenanstaltenverbund   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c WILHELMINEN HOSPITAL   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Adherence; Cognitive impairment; Depression; Diabetes mellitus; Mental disorders; Psychotropic drugs

Indexed keywords

ANTIDIABETIC AGENT;

AUSTRIA; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; HUMAN; MEDICATION COMPLIANCE; MENTAL DISORDERS; PRACTICE GUIDELINE; PSYCHOLOGY; TREATMENT OUTCOME;

AUSTRIA; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; MENTAL DISORDERS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84962641562     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-015-0939-8     Document Type: Article

References (51)

1. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412–24.
2. Fisher L, Plonsky WH, Hessler D, Mullan J. When is diabetes distress clinically meaningful? Diabetes Care. 2012;35:259–64.
3. American Diabetes Association. Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care and immunization. Sec. 4. in Standards of Medical Care in Diabetes – 2015. Diabetes Care. 2015;38 (Suppl 1):S20–30.
4. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144–58.
5. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and metaanalysis. Br J Psychiatry. 2008;192(6):406–11.
6. Katon W, Ming-Yu F, Unützer J, Taylor J, Pincus H, Schoenbaum M. Depression and diabetes: a potentially lethal combination. J Gen Intern Med. 2008;23(10):1571–5.
7. Sullivan MD, O’Connor P, Feeney P, et al. Depression predicts all-cause mortality. Epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care. 2012;35:1708–15.
8. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes. Diabetes Care. 2001;24:1069–78.
9. Abrahamian H, Hofmann P, Prager R, Toplak H. Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). Neuropsychiatr Dis Treat. 2009;5:261–6.
10. Knol MJ, Twisk JWR, Beekman ATF, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006;49:837–45.
11. Ali S, Stone A, Peters L, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23:1165–73.
12. Nicolucci A, Kovacs Burns K, Holt RI, et al. Diabetes attitudes, wishes and Needs second study (DAWN2): crossnational benchmarking of diabetes- related psychosocial outcomes for people with diabetes. Diabet med. 2013;30(7):767–77.
13. Gonzalez JS, Delahanty LM, Safren SA, Meigs JB, Grant RW. Differentiating symptoms of depression from diabetes-specific distress: relationships with self-care in type 2 diabetes. Diabetologia. 2008;51(10):1822–5.
14. Whooley MA, Avins AL, Miranda J, et al. Case-finding instrument for depression. J Gen Intern Med. 1997;12:439–45.
15. Hautzinger M, Keller F, Kühner C. Beck Depressions-Inventar (BDI-II). Revision. Frankfurt a. M.: Harcourt Test Services; 2006.
16. Herrmann-Lingen C, Buss U, Snaith RPHADS-D. Hospital Anxiety and Depression Scale – Deutsche Version. 3. aktualisierte Aufl. Bern: Huber; 2011.
17. Leitlinie der deutschen Diabetesgesellschaft. http://www.deutsche-diabetes-gesellschaft.de. Zugegriffen: 12. Aug. 2015.
18. Correll CU, Detraux J, Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World. Psychiatry. 2015;14:119–36.
19. Collins MM, Corcoran P, Perry IJ. Anxiety and depression symptoms in patients with diabetes. Diabet Med. 2009;26(2):153–61.
20. Ludman E, Katon W, Russo J, et al. Panic episodes among patients with diabetes. Gen Hosp Psychiatry. 2006;28:475–81.
21. Young-Hyman DL, Davis CL. Disordered eating behavior in individuals with diabetes. Diabetes Care. 2010;33:683–9.
22. Markowitz JT, Butler DA, Vokening LK, et al. Brief screening tool for disordered eating in diabetes: internal consistency and external validity in a contemporary sample of pediatric patients with type 1 diabetes. Diabetes Care. 2010;33:495–500.
23. Kahl KG, Greggersen W, Schweiger U, et al. Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. Eur Arch Psychiatry Clin Neurosci. 2013;263(3):205–13.
24. Mai Qu, CDÀrcy H, Sanfilippo FM, Emery JD, Preen DB. Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study. BMC Med. 2011;9:118.
25. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45–53.
26. Jones BJ, Gallagher BJ, Moss DM, McFalls JA. Obstetrical complications, social class and type of schizophrenia. Clin Schizophr Relat Psychoses. 2011;5(1):33–9.
27. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012;37(12):1901–11.
28. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes – systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460–9.
29. Seaquist E. The final frontier: how does diabetes affect the brain? Diabetes. 2010;59:4–5.
30. Jacobson AM, Musen G, Ryan CM, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007;356(18):1842–52.
31. Hershey T, Perantie DC, Wu J, Weaver PM, Black KJ, White NH. Hippocampal volumes in youth with type 1 diabetes. Diabetes. 2010;59(1):236–41.
32. Launer LJ, Miller ME, Williamson JD, et al. Effects of randomization to intensive glucose lowering on brain structure and function in type 2 diabetes ACCORD Memory in Diabetes Study. Lancet Neurol. 2011;10(11):969–77.
33. Ress C, Tschoner A, Kaser S, Ebenbichler C. Psychopharmaka und diabetes. Wien Med Wochenschr. 2011;161(21–22):531–42.
34. Bushe CJ, Leonard BE. Blood glucose and schizophrenia – a systematic review of prospective randomized clinical trials. J Clin Psychiatry. 2007;68(11):1682–90.
35. Prisciandaro JJ, Gebregziabher M, Grubaugh AL, Gilbert GE, Echols C, Egede LE. Impact of psychiatric comorbidity on mortality in veterans with type 2 diabetes. Diabetes Technol Ther. 2011;13(1):73–8.
36. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br J Psychiatry. 2004;184:58–62.
37. Funnell MM, Anderson RM. The problem with compliance in diabetes. JAMA. 2000;284(13):1709.
38. Delamater AM, Jacobson AM, Anderson B, Cox D, Fisher L, et al. Improving patient adherence. Clin Diabetes. 2006;24(2):71–7.
39. Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes. Diabetes Care. 2001;24:561–8.
40. Chatterjee JS. From compliance to concordance in diabetes. J Med Ethics. 2006;32:507–10.
41. Roberts SE, Goldacre MJ, Neil H. Mortality in young people admitted to hospital for diabetes: database study. BMJ. 2004;328(7442):741–2.
42. Von Mach MA, Gauer M, Meyer S, Omogbehin B, Schinzel H. Antidiabetic medications in overdose: a comparison of the inquiries made to a regional poisons unit regarding original sulfonylureas, biguanides and insulin. Int J Clin Pharmacol Ther. 2006;44(2):51–4.
43. Lustmann PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behaviour therapy for depression in type 2 diabetes mellitus. A randomized controlled trial. Ann Intern Med. 1998;129(8):613–21.
44. Bogner HR, Morales KH, de Vries HF, Cappola AR. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012;10(1):15–22.
45. Markowitz S, Gonzalez JS, Wilkinson JL, Safren SA. Treating depression in diabetes: emerging findings. Psychosomatics. 2011;52:1–18.
46. Georgiades A, Zucker N, Friedman KE, Mosunic CJ, Applegate K, et al. Changes in depressive symptoms and glycemic control in diabetes mellitus. Psychosom Med. 2007;69(3):235–41.
47. Steed L, Cooke D, Newman S. A systematic review of psychosocial outcomes following education, self-management and psychological interventions in diabetes mellitus. Patient Educ Couns. 2003;51(1):5–15.
48. Wang MY, Tsai PS, Chou KR, Chen CM. A systematic review of the efficacy of non-pharmacological treatments for depression on glycemic control in type 2 diabetics. J Clin Nurs. 2008;17(19):2524–30.
49. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Arch Gen Psychiatry. 2007;46:1123–31.
50. NICE. Schizophrenia: core intervention in the treatment and management of schizophrenia in adults in primary and secondary care. 2008. http://www.nice.org.uk/guidance/index.jsp?action=download&o=42139. Zugegriffen: 12. Aug. 2015.
51. Correll C, Detraux J, Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World. Psychiatry. 2015;14:119–36.